Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD

Study in Human iPSCs-derived Retinal Pigment Epithelium Cells Transplantation for Advanced (Late-stage) Age-Related Macular Degeneration

Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial Cells (hiPSC-RPEs) Subretinal Transplantation in Adanced (Late-Stage) Age-Related Macular Degeneration(AMD) Patients.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

12

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Recruiting
        • The First Affiliated Hospital with Nanjing Medical University
        • Contact:
          • Yue Wang
          • Phone Number: +86 13405818362

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • (1)Age ≥50 years and ≤85 years, regardless of gender.
  • (2)Patients with atrophic AMD in the macular area (geographic atrophy >250μm, involving the foveal center); or inactive neovascular AMD patients who have undergone treatment for wet AMD or have naturally converted to non-exudative AMD (referring to patients with fibrovascular scar formation, who are unresponsive to anti-VEGF treatment, and have no macular edema on OCT and/or no fluorescein leakage on FFA), with a scar diameter not exceeding 6 PD.
  • (3)Best-corrected visual acuity (BCVA) of the study eye ≥5 letters and ≤34 letters (using the ETDRS visual acuity chart).
  • (4)If both eyes meet the criteria, the more severely affected eye will be selected; if the severity is the same in both eyes, the right eye will be designated as the study eye.
  • (5)The patient or their legal representative has signed a written informed consent form.

Exclusion Criteria:

  • Ocular Diseases:
  • (1)Vitreous hemorrhage in the study eye within 2 months prior to screening.
  • (2)Presence of a scar or fibrosis involving the fovea in the study eye, or a peripheral scar area greater than 6 PD, indicating severe irreversible visual loss.
  • (3)Presence of pseudoexfoliation syndrome, central retinal vein occlusion, intraocular hemorrhage causing visual loss, rhegmatogenous retinal detachment, macular hole, or active choroidal neovascularization in the study eye.
  • (4)Afferent pupillary defect (APD) in the study eye.
  • (5)Significant media opacity in the study eye (excluding lens opacities) that may interfere with visual function assessment or fundus examination.
  • (6)Acute infectious inflammation in either eye during the screening period.
  • (7)Patients with intraocular pressure higher than 25 mmHg despite medical treatment.
  • (8)Monocular blind patients.

Ocular Treatments:

  • (9)The study eye has undergone focal/grid laser photocoagulation within 3 months prior to screening.
  • (10)The study eye has undergone any intraocular surgery within 3 months prior to screening.
  • (11) Any eye has received anti-angiogenic therapy (including any anti-VEGF agents, e.g., Aflibercept [Eylea®], Ranibizumab [Lucentis®], Bevacizumab [Avastin®]) within 1 month prior to screening; or has undergone cataract surgery within 1 month prior to screening with unstable postoperative ocular conditions.

Systemic Diseases, Treatments, and Other Conditions:

  • (12)Patients with an allergic reaction or history of allergy to sodium fluorescein and indocyanine green, a history of allergy to protein products used for treatment or diagnosis, and patients with allergies to two or more drugs and/or non-drug factors, or those currently suffering from allergic diseases.
  • (13)Patients with uncontrolled diabetes (fasting blood glucose ≥7.0 mmol/L or 2-hour postprandial blood glucose ≥11.1 mmol/L).
  • (14)Patients with a history of surgical procedures within 1 month prior to screening, or those with unhealed wounds, ulcers, fractures, etc.
  • (15)Patients with uncontrolled hypertension (defined as a single measurement of systolic blood pressure >180 mmHg, two consecutive measurements of systolic blood pressure >160 mmHg, or diastolic blood pressure >100 mmHg despite optimal treatment).
  • (16)Patients with a history of myocardial infarction within 6 months prior to enrollment.
  • (17)Patients with active disseminated intravascular coagulation or a significant tendency to bleed; patients who have used anticoagulant or antiplatelet aggregation drugs within 14 days prior to screening, except for aspirin/nonsteroidal anti-inflammatory drugs.
  • (18) Presence of any uncontrolled systemic clinical conditions, such as interstitial pneumonia, severe psychiatric, neurological, cardiovascular, or respiratory diseases, malignant tumors, Parkinson's disease, Alzheimer's disease, or other severe systemic disorders.
  • (19)Women of childbearing age with a positive pregnancy test during the screening period. Women who wish to breastfeed during the study period, and all patients of childbearing age (male and female) who do not agree to take effective contraceptive measures (such as intrauterine devices, oral contraceptives, or condoms) throughout the study period and for 30 days after the end of the visit period.
  • (20)Patients who have participated in or are currently participating in other clinical studies within 30 days prior to screening.
  • (21)Hemoglobin <100 g/L, platelets ≤100×10^9/L, neutrophil count <1.0×10^9/L, ALT/AST >1.5×upper limit of normal (ULN), creatinine >1.3 mg/dL.
  • (22)Subjects with any clinically significant finding in virological tests (HIV, HBV, HCV and TPPA).
  • (23)Patients deemed unsuitable for inclusion by the investigator, or other medical conditions that limit the subject's compliance, safety, or affect the results of the trial results.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HiO-630 Dose-Escalation Cohorts

Participants will receive a single subretinal injection of HiO-630. Three ascending dose cohorts are included: 200,000 cells/eye (low dose), 400,000 cells/eye (mid dose), and 600,000 cells/eye (high dose). Enrollment into the next higher-dose cohort will commence upon completion of safety assessment for the preceding cohort.

hiPSC-RPEs transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure

Other Names:
  • HiO-630

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence and Severity of Treatment-Related Adverse Events
Time Frame: Within 2 years after administration

Any adverse reactions/adverse events (AEs) related to hiPSC-RPEs treatment occurring within 2 years after the completion of hiPSC-RPEs administration in all subjects, and their severity (graded according to CTCAE criteria).

Within 2 years after administration

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of visual acuity using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart.
Time Frame: From enrollment to the end of study at 12 months

Best-corrected visual acuity (BCVA) of the study eye and fellow eye will be measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. Subjects wearing soft contact lenses shall remove the lenses and wait for 30 minutes prior to the examination.

Under standard illumination conditions, subjects wear their best refractive correction, occlude the non-tested eye, and identify letters line-by-line at a distance of 4 meters. One point is awarded for each correctly identified letter. If ≥20 letters are correctly identified at 4 meters, the ETDRS score equals the number of letters correctly read at 4 m plus 30. If fewer than 20 letters are correctly identified, testing of the first 6 lines will be performed at 1 meter, and the final score is the sum of correctly identified letters obtained at 4 m and 1 m.

From enrollment to the end of study at 12 months
Change-from-baseline in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) total score
Time Frame: From enrollment to the end of study at 12 months

NEI-VFQ-25 questionnaire will be used to assess trial participants. Uniformly trained investigators will administer each item following standardized instructions. Participants will respond based on their actual visual function and daily life experience, and investigators will record responses truthfully. Domain scores and the composite score will be calculated according to the NEI-VFQ-25 scoring rules. All scores are transformed to a scale ranging from 0 to 100, with higher scores indicating better visual function and visual-related quality of life.

From enrollment to the end of study at 12 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change-from-baseline in geographic atrophy lesion area measured by fundus autofluorescence (FAF) at 1 year post-treatment
Time Frame: From enrollment to the end of study at 12 months

Geographic atrophy lesion area will be assessed using fundus autofluorescence (FAF) imaging. Lesion area is measured in square millimeters (mm²).

From enrollment to the end of study at 12 months
Change-from-baseline in macular and graft-site retinal structure assessed by optical coherence tomography (OCT) at 1 year post-treatment
Time Frame: From enrollment to the end of study at 12 months

OCT examination will be performed on the study eye to measure the central macular retinal thickness. Cross-sectional images of the macular region and cell graft area will be acquired to evaluate the integrity of retinal layers, RPE and outer retinal structure, as well as abnormal findings such as intraretinal or subretinal fluid.

From enrollment to the end of study at 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Songtao Yuan, M.D., The First Affiliated Hospital with Nanjing Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 14, 2025

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

January 9, 2026

First Submitted That Met QC Criteria

February 11, 2026

First Posted (Actual)

February 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 13, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • JSPH-iPSCs-RPE-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.